我们在新冠病毒肺炎的药物治疗方面进展如何？ - Suppr

Suppr

超能文献

Where are we with drug treatments for covid-19?

作者信息

Baraniuk Chris

机构信息

Belfast, UK.

出版信息

BMJ. 2021 May 7;373:n1109. doi: 10.1136/bmj.n1109.

DOI:10.1136/bmj.n1109

PMID:33962913

Abstract

摘要

相似文献

Where are we with drug treatments for covid-19?我们在新冠病毒肺炎的药物治疗方面进展如何？

BMJ. 2021 May 7;373:n1109. doi: 10.1136/bmj.n1109.

Creation and maintenance of a table for assessment of evolving evidence for COVID-19-related treatments.创建并维护一个表格，用于评估与 COVID-19 相关治疗方法的证据演变情况。

Am J Health Syst Pharm. 2021 Jan 5;78(2):154-157. doi: 10.1093/ajhp/zxaa334.

Characteristics of registered clinical trials assessing treatments for COVID-19: a cross-sectional analysis.评估 COVID-19 治疗方法的注册临床试验特征：一项横断面分析。

BMJ Open. 2020 Jun 9;10(6):e039978. doi: 10.1136/bmjopen-2020-039978.

Clinical trials and the COVID-19 pandemic.临床试验与新冠疫情

Hell J Nucl Med. 2020 Jan-Apr;23(1):4-5. doi: 10.1967/s002449912014.

Drug Repurposing in the COVID-19 Era: Insights from Case Studies Showing Pharmaceutical Peculiarities.新冠疫情时代的药物重新利用：来自显示制药特性的案例研究的见解

Pharmaceutics. 2021 Feb 25;13(3):302. doi: 10.3390/pharmaceutics13030302.

Mortality and morbidity of curative and palliative anticancer treatments during the COVID-19 pandemic: A multicenter population-based retrospective study.COVID-19大流行期间根治性和姑息性抗癌治疗的死亡率和发病率：一项基于人群的多中心回顾性研究。

Mol Clin Oncol. 2021 Apr;14(4):82. doi: 10.3892/mco.2021.2244. Epub 2021 Feb 26.

Emerging and experimental treatments for COVID-19 and drug interactions with psychotropic agents.新型冠状病毒肺炎的新兴及实验性治疗方法以及与精神药物的药物相互作用。

Ther Adv Psychopharmacol. 2020 Jun 22;10:2045125320935306. doi: 10.1177/2045125320935306. eCollection 2020.

The under-reported role of toxic substance exposures in the COVID-19 pandemic.有毒物质暴露在新冠疫情中的作用被低估了。

Food Chem Toxicol. 2020 Nov;145:111687. doi: 10.1016/j.fct.2020.111687. Epub 2020 Aug 14.

Highly efficient clinical trial designs for reliable screening of under-performing treatments: Application to the COVID-19 Pandemic.用于可靠筛选疗效不佳治疗方法的高效临床试验设计：在新冠疫情中的应用。

Clin Trials. 2020 Oct;17(5):483-490. doi: 10.1177/1740774520940227. Epub 2020 Jul 15.

Targeted, Site-Specific, Delivery Vehicles of Therapeutics for COVID-19 Patients. Brief Review.针对 COVID-19 患者的靶向、特定部位、治疗药物的递药载体。简要综述。

Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620954911. doi: 10.1177/1076029620954911.

引用本文的文献

TRPC6 inhibitor (BI 764198) to reduce risk and severity of ARDS due to COVID-19: a phase II randomised controlled trial.TRPC6 抑制剂（BI 764198）降低 COVID-19 所致 ARDS 的风险和严重程度：一项 II 期随机对照试验。

Thorax. 2023 Aug;78(8):816-824. doi: 10.1136/thorax-2022-219668. Epub 2023 Apr 6.

Long COVID prevalence and physiology-centered risks: population-based study in Ukraine.长新冠患病率和以生理为中心的风险：乌克兰基于人群的研究。

Inflammopharmacology. 2023 Apr;31(2):597-602. doi: 10.1007/s10787-023-01177-1. Epub 2023 Mar 22.

Approved HIV reverse transcriptase inhibitors in the past decade.过去十年中获批的HIV逆转录酶抑制剂。

Acta Pharm Sin B. 2022 Apr;12(4):1567-1590. doi: 10.1016/j.apsb.2021.11.009. Epub 2021 Nov 16.

Clinical Effectiveness of Regdanvimab Treatment for Mild-to-Moderate COVID-19: A Retrospective Cohort Study.瑞得昔单抗治疗轻至中度新型冠状病毒肺炎的临床疗效：一项回顾性队列研究

Curr Ther Res Clin Exp. 2022;96:100675. doi: 10.1016/j.curtheres.2022.100675. Epub 2022 May 16.

Debate on mandatory COVID-19 vaccination.关于新冠病毒强制接种疫苗的辩论。

Ethics Med Public Health. 2022 Apr;21:100761. doi: 10.1016/j.jemep.2022.100761. Epub 2022 Jan 24.

Relative risks of COVID-19 fatality between the first and second waves of the pandemic in Ontario, Canada.加拿大安大略省第一波和第二波大流行期间 COVID-19 病死率的相对风险。

Int J Infect Dis. 2021 Aug;109:189-191. doi: 10.1016/j.ijid.2021.06.059. Epub 2021 Jul 1.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验